A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

Summary

To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1912.

Timeline

Start

2021-12-22

Primary completion

2024-03-31

Completion

2025-03-30

Drugs

Indications